Bioxyne Limited · ASX:BXN
Bioxyne — Shareholder Meeting (November 2023)
10 slides from Bioxyne's shareholder meeting presentation, Nov 17, 2023
Slide 1: AGM Deck FY 2024
For personal use only FY 2024 AGM DECK www.bioxyne.com BXN:ASX .com.au
Slide 2: Table of Contents
Table of CONTENTS For personal use only 1 2 3 4 5 Front Page Table of Contents Introduction Executive Australia Summary 6 7 8 9 10 UK/EU Japan Revenue by Product Showcase End. Segment & Country
Slide 3: Introduction: A Novel Approach to Healthcare
INTRODUCTION A NOVEL APPROACH TO HEALTHCARE For personal use only EXTRAORDINARY RESULTS Our mission is better healthcare with novel drugs and consumer products: To treat cancer and pain with a plant, depression with a single dose of a mushroom, prevent and reduce the prevalence of these diseases thr
Slide 4: Executive Summary: Breathing New Life into BXN:ASX
Executive Summary BREATHING NEW LIFE INTO BXN:ASX For personal use only Bioxyne (BXN:ASX) has been publicly listed since 2006, and its primary business supplying its patented PCC probiotics to the USA. In May 2023 Bioxyne acquired Breathe Life Sciences Pty Ltd (“BLS”) in an all stock deal valued at
Slide 5: BLS Australia
ODC IMPORT LICENSE NO. 2323395 ODC EXPORT LICENSE NO. 2323396 GMP CERTIFICATE NO. (PENDING.201123) QLD HEALTH WHOLESALE LICENCE NO. MWL010291721 BLS Australia OUT WITH THE OLD, IN WITH THE NEW (PHARMACEUTICALS) For personal use only B2B wholesale of starting materials, APIs, and manufactured medicin
Slide 6: BLS UK & Europe
ODC IMPORT LICENSE NO. 2323395 ODC EXPORT LICENSE NO. 2323396 GMP CERTIFICATE NO. (PENDING.201123) QLD HEALTH WHOLESALE LICENCE NO. MWL010291721 BLS UK & Europe LIFE SCIENCES: MORE THAN JUST PHARMACEUTICALS For personal use only B2B wholesale of raw materials (Cannabis & other, for novel foods & wel
Slide 7: BLS Japan
ODC IMPORT LICENSE NO. 2323395 ODC EXPORT LICENSE NO. 2323396 GMP CERTIFICATE NO. (PENDING.201123) QLD HEALTH WHOLESALE LICENCE NO. MWL010291721 BLS Japan 花より団子 HANA YORI DANGO For personal use only One of only few companies capable of importing cannabis derived materials into Japan. B2B wholesale o
Slide 8: Revenue % of Total by Business Segment - Forecast
Revenue % of Total by Business Segment - Forecast PRESCRIPTION DR WATSON PRODUCTS KEY GROWTH DRIVER For personal use only WL Manufacturing USA 6.9% 12.8% Prescription Products Dr Watson 40.3% Japan Australia 15.4% 41% B2B APIs/ Materials 42.4% UK/EU Health Products Dr Watson 30.8% 10.4%
Slide 9: Product Showcase
For personal use only Product Showcase
Slide 10: End.
End. For personal use only FY 2024 AGM DECK www.bioxyne.com BXN:ASX .com.au